an introduction to the maxilus study: the optimal dose of luspatercept in lr-mds
Published 2 weeks ago • 14 plays • Length 0:48Download video MP4
Download video MP3
Similar videos
-
4:21
evaluating luspatercept in combination with esas for the treatment of anemia in lr-mds
-
2:52
long-term evaluation of luspatercept in esa-intolerant/refractory lr-mds: medalist follow-up study
-
2:14
trial updates for luspatercept in lr-mds: commands, medalist and elements-mds
-
1:00
findings from the commands study and the approval of luspatercept for lower-risk mds
-
1:51
factors driving the transformation of chip to mds
-
1:40
long-term follow-up of luspatercept: response duration and progression to aml
-
14:53
chapter 1: introduction to hematology
-
5:34
does thrombocytosis = cancer?
-
5:37
reblozyl® (luspatercept-aamt) mechanism of action in anaemia
-
2:30
medalist: luspatercept and erythropoiesis biomarkers in mds
-
2:49
the role of the immune system in the pathophysiology of mds
-
1:15
luspatercept for the treatment of patients with lower-risk mds and esa failure
-
1:17
phase ii study of tosedostat in mds
-
2:31
emerging treatment options for patients with esa-refractory mds: luspatercept & imetelstat
-
3:17
pre-mds states: novel therapeutic approaches, and determining appropriate trial endpoints
-
2:06
an insight into the challenges and management of myeloproliferative neoplasm-unclassifiable (mpn-u)
-
2:15
independence: luspatercept vs placebo in mpns-associated myelofibrosis
-
1:03
most: an observational study of myelofibrosis and essential thrombocythemia
-
2:29
the 7th esh translational research e-conference on mds
-
4:48
alan list: is luspatercept a new option for patients with mds?
-
1:45
what's new in myeloproliferative neoplasms?